Severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) has a high death rate in patients with comorbidities or in an immunocompromised state. We report a mild and attenuated SARS CoV-2 infection in a patient who is 17 months post stem cell transplantation and maintained on the JAK/STAT inhibitor ruxolitinib, a proposed novel therapy for SARS CoV-2 pneumonia.
All Keywords
【저자키워드】 COVID-19, Immunocompromised, Allogeneic stem cell transplantation, Graft-versus-host disease, JAK inhibitor.,
【저자키워드】 COVID-19, Immunocompromised, Allogeneic stem cell transplantation, Graft-versus-host disease, JAK inhibitor.,